Is hypertension an immunologic disease?

Current Cardiology Reports

Volumn 10, Issue 6, 2008, Pages 464-469

  Harrison, David G ^a   Guzik, Tomasz J ^b   Goronzy, Jorg ^b   Weyand, Cornelia ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROHORMONE; SODIUM; T LYMPHOCYTE RECEPTOR;

ADAPTIVE IMMUNITY; ADRENERGIC NERVE; ADRENERGIC TRANSMISSION; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; EFFECTOR CELL; GRAFT REJECTION; HORMONE ACTION; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; INTRAABDOMINAL FAT; KIDNEY FAILURE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION;

BLOOD PRESSURE; CYTOKINES; HUMANS; HYPERTENSION; IMMUNITY, INNATE; INFLAMMATION; INTRA-ABDOMINAL FAT; RECEPTOR, ANGIOTENSIN, TYPE 1; RISK FACTORS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VASOCONSTRICTION;

EID: 58249088876     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0073-6     Document Type: Article

References (51)

1. Shepherd JT: Franz Volhard lecture. Increased systemic vascular resistance and primary hypertension: The expanding complexity. J Hypertens Suppl 1990, 8:S15-S27.
2. Garovic VD, Hilliard AA, Turner ST: Monogenic forms of low-renin hypertension. Nat Clin Pract Nephrol 2006, 2:624-630.
3. Crowley SD, Gurley SB, Herrera MJ, et al.: Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006, 103:17985-17990.
4. Mangiapane MLF Simpson JB: Subfornical organ: forebrain site of pressor and dipsogenic action of angiotensin II. Am J Physiol 1980, 239:R382-R389.
5. Brody MJ: Central nervous system and mechanisms of hypertension. Clin Physiol Biochem 1988, 6:230-239.
6. Blake GJ, Rifai N, Buring JE, et al.: Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003, 108:2993-2999.
7. Svendsen UG: Evidence for an initial, thymus independent and a chronic, thymus dependent phase of DOCA and salt hypertension in mice. Acta Pathol Microbiol Scand [A] 1976, 84:523-528.
8. Tian N, Gu JW, Jordan S, et al.: Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 2007, 292:H1018-H1025.
9. Mattson DL, James L, Berdan EA, et al.: Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 2006, 48:149-156.
10. Bravo Y, Quiroz Y, Ferrebuz A, et al.: Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol 2007, 293:F616-F623.
11. Pechman KR, Basile DP, Lund H, et al.: Immune suppression blocks sodium-sensitive hypertension following recovery from ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 2008, 294:R1234-R1239.
12. Herrera J, Ferrebuz A, Macgregor EG, et al.: Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 2006, 17:S218-S225.
13. Panoulas VF, Douglas KM, Milionis HJ, et al.: Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:1477-1482.
14. Neimann AL, Shin DB, Wang X, et al.: Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006, 55:829-835.
15. Matthiesen L, Berg G, Ernerudh J, et al.: Immunology of preeclampsia. Chem Immunol Allergy 2005, 89:49-61.
16. Mahmoud F, Omu A, Abul H, et al.: Lymphocyte subpopulations in pregnancy complicated by hypertension. J Obstet Gynaecol 2003, 23:20-26.
17. Franco M, Martinez F, Quiroz Y, et al.: Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. Am J Physiol 2007, 293:R251-R256.
18. Nava M, Quiroz Y, Vaziri N, et al.: Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol 2003, 284:F447-F454.
19. Rodriguez-Iturbe B, Quiroz Y, Nava M, et al.: Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002, 282:F191-F201.
20. Seaberg EC, Munoz A, Lu M, et al.: Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005, 19:953-960.
21. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, et al.: Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: All for one and one for all. Am J Physiol Renal Physiol 2004, 286:F606-F616.
22. Fu ML: Do immune system changes have a role in hypertension? J Hypertens 1995, 13:1259-1265.
23. Dzielak DJ: The immune system and hypertension. Hypertension 1992, 19:I36-I44.
24. Dzielak DJ: Immune mechanisms in experimental and essential hypertension. Am J Physiol 1991, 260:R459-R467.
25. Kawanishi M: Nitric oxide inhibits Epstein-Barr virus DNA replication and activation of latent EBV. Intervirology 1995, 38:206-213.
26. Jimenez R, Belcher E, Sriskandan S, et al.: Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proc Natl Acad Sci U S A 2005, 102:4637-4642.
27. Miller YI, Chang MK, Binder CJ, et al.: Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol 2003, 14:437-445.
28. Abbas A, Lichtman A, eds: Cellular and Molecular Immunology, edn 5. Philadelphia, PA: Elsevier Saunders; 2005.
29. Shimada K, Yazaki Y: Binding sites for angiotensin II in human mononuclear leucocytes. J Biochem 1978, 84:1013-1015.
30. Nataraj C, Oliverio MI, Mannon RB, et al.: Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999, 104:1693-1701.
31. Amuchastegui SC, Azzollini N, Mister M, et al.: Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998, 9:1948-1955.
32. Furukawa Y, Matsumori A, Hirozane T, et al.: Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation 1996, 93:333-339.
33. Booster MH, Yin M, Maessen JG, et al.: Protection of canine renal grafts by renin-angiotensin inhibition through nucleoside transport blockade. Transpl Int 1995, 8:207-213.
34. Otsuka F, Yamauchi T, Kataoka H, et al.: Effects of chronic inhibition of ACE and AT1 receptors on glomerular injury in Dahl salt-sensitive rats. Am J Physiol 1998, 274:R1797-R1806.
35. Velasquez MT, Striffler JS, Abraham AA, et al.: Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. Hypertension 1997, 30:1232-1237.
36. Shibouta Y, Chatani F, Ishimura Y, et al.: TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats. Kidney Int Suppl 1996, 55:S115-S118.
37. Shao J, Nangaku M, Miyata T, et al.: Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003, 42:31-38.
38. Fernandez-Castelo S, Arzt ES, Pesce A, et al.: Angiotensin II regulates interferon-gamma production. J Interferon Res 1987, 7:261-268.
39. Diet F, Pratt RE, Berry GJ, et al.: Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996, 94:2756-2767.
40. Potter DD, Sobey CG, Tompkins PK, et al.: Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998, 98:800-807.
41. Danilov SM, Sadovnikova E, Scharenborg N, et al.: Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp Hematol 2003, 31:1301-1309.
42. Guruli G, Pflug BR, Pecher S, et al.: Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood 2004, 104:2107-2115.
43. Guzik TJ, Hoch NE, Brown KA, et al.: Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007, 204:2449-2460.
44. Elmarakby AA, Quigley JE, Pollock DM, et al.: Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 2006, 47:557-562.
45. Jonasson L, Holm J, Skalli O, et al.: Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986, 6:131-138.
46. Jonasson L, Holm J, Skalli O, et al.: Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985, 76:125-131.
47. Agrewala JN, Brown DM, Lepak NM, et al.: Unique ability of activated CD4+ T cells but not rested effectors to migrate to non-lymphoid sites in the absence of inflammation. J Biol Chem 2007, 282:6106-6115.
48. Wu H, Ghosh S, Perrard XD, et al.: T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007, 115:1029-1038.
49. Angeli F, Verdecchia P, Pellegrino C, et al.: Association between periodontal disease and left ventricle mass in essential hypertension. Hypertension 2003, 41:488-492.
50. Vlachopoulos C, Dima I, Aznaouridis K, et al.: Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005, 112:2193-2200.
51. Clapp BR, Hingorani AD, Kharbanda RK, et al.: Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res 2004, 64:172-178.